 |
6 Diseases |  |
0 Trials |
|
0 Trials |  |
14 News |  |
- || GSK2618960 / GSK
Clinical, P1 data, Journal: Characterization of the robust humoral immune response to GSK2618960, a humanized anti-IL-7 receptor monoclonal antibody, observed in healthy subjects in a Phase 1 study. (Pubmed Central) - Oct 20, 2021
GSK2618960 treatment of PBMCs increased the proportion of DC cells showing an increase in expression of CD83, CD86 and CD209, which indicated enhanced DC differentiation and activation relative to the isotype control anti-β amyloid antibody. Collectively, the evidence supports that the high incidence of observed clinical immunogenicity was likely related to the receptor-mediated activity by GSK2618960.
- | CSJ117 / Novartis, MorphoSys, tezepelumab (AMG 157) / AstraZeneca, Amgen, GSK2618960 / GSK
Journal: Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. (Pubmed Central) - Apr 2, 2021
Inhaled anti-TSLP is an alternative route currently under evaluation. The long-term safety and efficacy of TSLP blockade need to be evaluated.
- || GSK2618960 / GSK
Clinical, Journal: Anti-IL-7 receptor α monoclonal antibody (GSK2618960) in healthy subjects - a randomised, double-blind placebo-controlled study. (Pubmed Central) - Mar 4, 2020
Although there was no discernible impact on peripheral T cell subsets in healthy subjects, GSK2618960 may effectively modulate auto-inflammatory activity of pathogenic T cells in diseased tissue. A relatively short half-life likely results from target-mediated rather than ADA-mediated clearance.
- GSK2618960 / GSK
Trial primary completion date: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of Mechanism of GSK2618960 in Primary Sjögren's Syndrome (pSS) (clinicaltrials.gov) - Jan 5, 2018
P2a, N=0, Withdrawn, Sponsor: GlaxoSmithKline
A relatively short half-life likely results from target-mediated rather than ADA-mediated clearance. Trial primary completion date: Jun 2020 --> Oct 2017
- GSK2618960 / GSK
Enrollment change, Trial withdrawal: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of Mechanism of GSK2618960 in Primary Sjögren's Syndrome (pSS) (clinicaltrials.gov) - Nov 17, 2017
P2a, N=0, Withdrawn, Sponsor: GlaxoSmithKline
Trial primary completion date: Jun 2020 --> Oct 2017 N=22 --> 0 | Recruiting --> Withdrawn
- | GSK2618960 / GSK
Enrollment open: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of Mechanism of GSK2618960 in Primary Sjögren's Syndrome (pSS) (clinicaltrials.gov) - Nov 13, 2017
P2a, N=22, Recruiting, Sponsor: GlaxoSmithKline
N=22 --> 0 | Recruiting --> Withdrawn Not yet recruiting --> Recruiting
- | GSK2618960 / GSK
New P2a trial: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of Mechanism of GSK2618960 in Primary Sjögren's Syndrome (pSS) (clinicaltrials.gov) - Aug 24, 2017
P2a, N=22, Not yet recruiting, Sponsor: GlaxoSmithKline
- | GSK2618960 / GSK
Trial completion: Single Ascending Doses Study of Anti- Interleukin-7 Receptor ? Monoclonal Antibody (GSK2618960) in Healthy Volunteers (clinicaltrials.gov) - Sep 14, 2015
P1, N=18, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- GSK2618960 / GSK
Enrollment closed: Single Ascending Doses Study of Anti- Interleukin-7 Receptor ? Monoclonal Antibody (GSK2618960) in Healthy Volunteers (clinicaltrials.gov) - Feb 9, 2015
P1, N=18, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- GSK2618960 / GSK
Enrollment open: Single Ascending Doses Study of Anti- Interleukin-7 Receptor ? Monoclonal Antibody (GSK2618960) in Healthy Volunteers (clinicaltrials.gov) - Dec 18, 2014
P1, N=18, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | GSK2618960 / GSK
New P1 trial: Single Ascending Doses Study of Anti- Interleukin-7 Receptor ? Monoclonal Antibody (GSK2618960) in Healthy Volunteers (clinicaltrials.gov) - Nov 18, 2014
P1, N=18, Not yet recruiting, Sponsor: GlaxoSmithKline
- GSK2618960 / GSK
Trial termination: A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Nov 6, 2013
P1, N=16, Terminated, Sponsor: GlaxoSmithKline
Recruiting --> Terminated; GSK confirmed misrepresentation of preclinical data that supported the rationale for GSK2618960 in MS. This decreased benefit assessment for MS
- GSK2618960 / GSK
Enrollment change: A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Nov 6, 2013
P1, N=16, Terminated, Sponsor: GlaxoSmithKline
This decreased benefit assessment for MS N=68 --> 16
- GSK2618960 / GSK
New P1 trial: A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Mar 7, 2013
P1, N=16, Terminated, Sponsor: GlaxoSmithKline